11.09.2017

As we all know different Risk-Sharing Models (RSM) have been varyingly in use in different western countries for the past 15 years. The enthusiasm about these models has been varying but we can say that in the last three to five years the models have enjoyed a real renaissance, mainly due to the market entry of several new pharmaceuticals aimed for rare diseases and with a relatively high price. Now the models are taking wider stand also in Finland, the first national RSM was approved by the Pharmaceutical Pricing Board (PPB) last week and to our understanding there are several others on the way.

In hospitals, these confidential agreements, however, have been in use for a longer time already. Unfortunately, the knowledge about their quantity, their structures and especially the experiences of such agreements is sparse, virtually non-existent.

In order to gather this hidden knowledge and use it in the future when building risk-sharing models that are beneficial for all parties involved, Medaffcon has executed the Risk Sharing Models in Finnish Hospitals 2017-study. The structure of the study follows Morgan et al’s study (Health Policy, Volume 121, Issue 4, April 2017) quite closely. This setup enables us to compare the situation in Finland to other western societies as well as to do follow-up studies at certain intervals in order to see how fast and wide the penetration of these models is.